JP7387926B2 - 選択的エストロゲン受容体分解剤の調製のためのプロセス - Google Patents

選択的エストロゲン受容体分解剤の調製のためのプロセス Download PDF

Info

Publication number
JP7387926B2
JP7387926B2 JP2023013779A JP2023013779A JP7387926B2 JP 7387926 B2 JP7387926 B2 JP 7387926B2 JP 2023013779 A JP2023013779 A JP 2023013779A JP 2023013779 A JP2023013779 A JP 2023013779A JP 7387926 B2 JP7387926 B2 JP 7387926B2
Authority
JP
Japan
Prior art keywords
compound
salt
formula
compounds
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023013779A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023112696A (ja
JP2023112696A5 (https=
Inventor
デルガド，アロンソ ホセ アルゲリェス
パットン チェル，ダグラス
アンドリュー マグナス，ニコラス
アルノルドヴィチ ゼスキス，ボリス
カーン グエン ホーク，マイ
ルー，ユー
マイケル レミック，デイビッド
Original Assignee
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2023112696A publication Critical patent/JP2023112696A/ja
Priority to JP2023138310A priority Critical patent/JP7805336B2/ja
Publication of JP2023112696A5 publication Critical patent/JP2023112696A5/ja
Application granted granted Critical
Publication of JP7387926B2 publication Critical patent/JP7387926B2/ja
Priority to JP2025146941A priority patent/JP2025183283A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
    • B01J23/44—Palladium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/022—Boron compounds without C-boron linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
JP2023013779A 2022-02-01 2023-02-01 選択的エストロゲン受容体分解剤の調製のためのプロセス Active JP7387926B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023138310A JP7805336B2 (ja) 2022-02-01 2023-08-28 選択的エストロゲン受容体分解剤の調製のためのプロセス
JP2025146941A JP2025183283A (ja) 2022-02-01 2025-09-04 選択的エストロゲン受容体分解剤の調製のためのプロセス

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263305520P 2022-02-01 2022-02-01
US63/305,520 2022-02-01
US202263409060P 2022-09-22 2022-09-22
US63/409,060 2022-09-22

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023138310A Division JP7805336B2 (ja) 2022-02-01 2023-08-28 選択的エストロゲン受容体分解剤の調製のためのプロセス

Publications (3)

Publication Number Publication Date
JP2023112696A JP2023112696A (ja) 2023-08-14
JP2023112696A5 JP2023112696A5 (https=) 2023-09-05
JP7387926B2 true JP7387926B2 (ja) 2023-11-28

Family

ID=85382684

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2023013779A Active JP7387926B2 (ja) 2022-02-01 2023-02-01 選択的エストロゲン受容体分解剤の調製のためのプロセス
JP2023138310A Active JP7805336B2 (ja) 2022-02-01 2023-08-28 選択的エストロゲン受容体分解剤の調製のためのプロセス
JP2025146941A Pending JP2025183283A (ja) 2022-02-01 2025-09-04 選択的エストロゲン受容体分解剤の調製のためのプロセス

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023138310A Active JP7805336B2 (ja) 2022-02-01 2023-08-28 選択的エストロゲン受容体分解剤の調製のためのプロセス
JP2025146941A Pending JP2025183283A (ja) 2022-02-01 2025-09-04 選択的エストロゲン受容体分解剤の調製のためのプロセス

Country Status (15)

Country Link
US (1) US11926634B2 (https=)
EP (1) EP4472982A1 (https=)
JP (3) JP7387926B2 (https=)
KR (2) KR20250006312A (https=)
AU (2) AU2023216654B2 (https=)
CA (1) CA3243621A1 (https=)
CO (1) CO2024009411A2 (https=)
CR (1) CR20240283A (https=)
DO (1) DOP2024000150A (https=)
IL (1) IL313886A (https=)
JO (1) JOP20240169A1 (https=)
MX (1) MX2024009453A (https=)
PE (1) PE20241731A1 (https=)
TW (2) TWI863110B (https=)
WO (1) WO2023150056A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020137965A (ja) * 2019-03-01 2020-09-03 株式会社三洋物産 遊技機
US20240199629A1 (en) * 2022-02-01 2024-06-20 Eli Lilly And Company Processes for the preparation of selective estrogen receptor degraders

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080221163A1 (en) 2005-01-18 2008-09-11 Jeffrey Alan Dodge Selective Estrogen Receptor Modulators
JP2016522262A (ja) 2013-06-19 2016-07-28 セラゴン ファーマシューティカルズ， インク． アゼチジンエストロゲン受容体調節因子及びその使用
JP2018504384A (ja) 2014-12-18 2018-02-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト エストロゲン受容体モジュレーター及びその使用
WO2021178846A1 (en) 2020-03-06 2021-09-10 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-associated diseases
JP2021530484A (ja) 2018-07-12 2021-11-11 イーライ リリー アンド カンパニー 選択的エストロゲン受容体分解剤
JP2021530486A (ja) 2018-07-12 2021-11-11 イーライ リリー アンド カンパニー 選択的エストロゲン受容体分解剤
WO2022192203A1 (en) 2021-03-09 2022-09-15 Eli Lilly And Company Methods of treating cancer using a combination of serd dosing regimens
WO2022197528A1 (en) 2021-03-16 2022-09-22 Eli Lilly And Company Selective estrogen receptor degraders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1709021B1 (en) 2004-01-22 2010-08-04 Eli Lilly And Company Selective estrogen receptor modulators for the treatment of vasomotor symptoms
EP2343287A1 (en) * 2009-12-10 2011-07-13 Almirall, S.A. New 2-aminothiadiazole derivatives
CN103582637B (zh) * 2011-05-17 2015-08-12 弗·哈夫曼-拉罗切有限公司 酪氨酸激酶抑制剂
US11014915B2 (en) * 2019-07-22 2021-05-25 Sun Pharma Advanced Research Company Limited Selective estrogen receptor degrader
CN115867282B (zh) * 2020-03-26 2025-05-27 奈克斯拉制药英国有限公司 用于抗癌的5-氨基-8-(4-吡啶基)-[1,2,4]三唑并[4,3-c]嘧啶-3-酮化合物
AR123185A1 (es) * 2020-08-10 2022-11-09 Novartis Ag Compuestos y composiciones para inhibir ezh2

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080221163A1 (en) 2005-01-18 2008-09-11 Jeffrey Alan Dodge Selective Estrogen Receptor Modulators
JP2016522262A (ja) 2013-06-19 2016-07-28 セラゴン ファーマシューティカルズ， インク． アゼチジンエストロゲン受容体調節因子及びその使用
JP2018504384A (ja) 2014-12-18 2018-02-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト エストロゲン受容体モジュレーター及びその使用
JP2021530484A (ja) 2018-07-12 2021-11-11 イーライ リリー アンド カンパニー 選択的エストロゲン受容体分解剤
JP2021530486A (ja) 2018-07-12 2021-11-11 イーライ リリー アンド カンパニー 選択的エストロゲン受容体分解剤
WO2021178846A1 (en) 2020-03-06 2021-09-10 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-associated diseases
WO2022192203A1 (en) 2021-03-09 2022-09-15 Eli Lilly And Company Methods of treating cancer using a combination of serd dosing regimens
WO2022197528A1 (en) 2021-03-16 2022-09-22 Eli Lilly And Company Selective estrogen receptor degraders

Also Published As

Publication number Publication date
MX2024009453A (es) 2024-08-09
CA3243621A1 (en) 2023-08-10
EP4472982A1 (en) 2024-12-11
US11926634B2 (en) 2024-03-12
JP2023112696A (ja) 2023-08-14
KR102743629B1 (ko) 2024-12-17
AU2025234145A1 (en) 2025-10-02
KR20250006312A (ko) 2025-01-10
US20230242545A1 (en) 2023-08-03
DOP2024000150A (es) 2024-08-30
AU2023216654B2 (en) 2025-09-25
TWI863110B (zh) 2024-11-21
JOP20240169A1 (ar) 2024-07-30
TW202523669A (zh) 2025-06-16
KR20240135862A (ko) 2024-09-12
CO2024009411A2 (es) 2024-07-29
JP2023162334A (ja) 2023-11-08
IL313886A (en) 2024-08-01
CR20240283A (es) 2024-09-03
WO2023150056A1 (en) 2023-08-10
JP7805336B2 (ja) 2026-01-23
TW202346300A (zh) 2023-12-01
PE20241731A1 (es) 2024-08-19
AU2023216654A1 (en) 2024-07-11
JP2025183283A (ja) 2025-12-16

Similar Documents

Publication Publication Date Title
US8354528B2 (en) Process for making thienopyrimidine compounds
JP2025183283A (ja) 選択的エストロゲン受容体分解剤の調製のためのプロセス
IL300463A (en) Process for the preparation of two derivatives of 4-{[(2S)-2-{4-[5-chloro-2-(1H-3,2,1-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridine -1-(2H)-yl}butenoyl]amino}-2-fluorobenzamide
JP2022513934A (ja) 置換複素環縮合γ－カルボリンの合成
CN108137588B (zh) 三环稠合吡啶-2-酮衍生物及其作为brd4抑制剂的用途
US11319326B2 (en) Tricyclic fused derivatives of 1-(cyclo)alkyl pyrtdin-2-one useful for the treatment of cancer
JP7347852B2 (ja) 重水素化大環状化合物の調製方法
US20240199629A1 (en) Processes for the preparation of selective estrogen receptor degraders
CN102216274A (zh) (R)-3-(2,3-二羟基丙基)-6-氟-5-(2-氟-4-碘苯基氨基)-8-甲基吡啶并[2,3-d]嘧啶-4,7(3H,8H)-二酮及其中间体的制备方法
BR112024013443B1 (pt) Processos para a preparação de degradadores seletivos de receptores de estrogênio
CN118647619A (zh) 选择性雌激素受体降解剂的制备方法
BR122025017409A2 (pt) Compostos degradadores seletivos de receptores de estrogênio
BR122025017416A2 (pt) Compostos degradadores seletivos de receptores de estrogênio
HK1248686B (zh) 适用於治疗癌症的1-(环)烷基吡啶-2-酮的三环稠合衍生物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230828

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230828

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20230828

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231027

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231115

R150 Certificate of patent or registration of utility model

Ref document number: 7387926

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150